Life Sciences & Biotechnology
Title : | Combating the Undruggable Ternary EGFR L858R-T790M-C797S Mutation Associated with Osimertinib for the Treatment of Non-Small Cell Lung Cancer (NSCLC) |
Area of research : | Life Sciences & Biotechnology |
Focus area : | Pharmaceutical chemistry |
Principal Investigator : | Dr. Harun M. Patel,
Associate Professor,
R.C. Patel College of Pharmacy, Shirpur |
Timeline Start Year : | 2023 |
Timeline End Year : | 2025 |
Contact info : | hpatel_38@yahoo.com |
Details
Executive Summary : | The US FDA approved Osimertinib (AZD9291) for treating metastatic EGFR-T790M NSCLC. However, a significant number of patients developed a C797S mutation, rendering Osimertinib resistant. This suggests a need for drugs to overcome this resistance obstacle. The current proposal focuses on designing and synthesizing fourth-generation triple mutant selective EGFR-L858R-T790M-C797S tyrosine kinase inhibitors to overcome this resistance in NSCLC chemotherapy. |
Total Budget (INR): | 44,61,020 |
Organizations involved
